Skip to main content
Erschienen in: Journal of Endocrinological Investigation 3/2019

01.03.2019 | Short Review

Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review

verfasst von: D. Magalhães, I. L. Sampaio, G. Ferreira, P. Bogalho, D. Martins-Branco, R. Santos, H. Duarte

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Insulinomas are a rare type of pancreatic neuroendocrine tumours characterized by insulin hypersecretion. They are considered malignant when metastases are present. Traditional therapies often promote only temporarily symptomatic relief and may be associated with severe adverse effects. There is scarce experience in treating malignant insulinomas with peptide receptors radionuclide therapy (PRRNT).

Patients and methods

We describe PRRNT results in four patients with inoperable malignant insulinomas with poorly controllable hypoglycaemia. All patients received therapy with 177Lu-DOTA-TATE after conventional therapies failed in controlling disease progression and symptoms. The activity administered per cycle was 4.8–7.4 GBq. The interval between cycles was 10–16 weeks. Haematology, liver and kidney function tests were performed before treatment initiation and 5 and 10 weeks after each cycle.

Results

Patient 1 presented significant clinical benefit for 13 months after PRRNT, with imaging improvement. Patient 2 obtained reduction of the number and severity of hypoglycaemic episodes during 15 months after therapy. Patient 3 is asymptomatic since PRRNT first cycle performed 23 months ago and revealed significant imaging improvement. Patient 4 had resolution of hypoglycaemia only 3 days after PRRNT first cycle and today, 16 months after therapy, the disease seems to be in remission and the patient maintains euglycaemic state. PRRNT was well tolerated, with only hematologic grade 2 toxicity in patient 1 and mild kidney toxicity in patient 3.

Conclusions

After the start of 177Lu-DOTA-TATE all patients achieved hypoglycaemia symptomatic control and had evident improvement of their quality of life. Three patients showed imagiological improvement suggesting reduced tumour load.
Literatur
1.
Zurück zum Zitat Albu A, Zirnea A, Georgescu O, Terzea D, Jinga D, Fica S (2008) Malignant insulinoma with hepatic and pulmonary metastases associated with primary hyperparathyroidism. Case report and review of the literature. J Med Life 1(2):210–217PubMed Albu A, Zirnea A, Georgescu O, Terzea D, Jinga D, Fica S (2008) Malignant insulinoma with hepatic and pulmonary metastases associated with primary hyperparathyroidism. Case report and review of the literature. J Med Life 1(2):210–217PubMed
2.
Zurück zum Zitat van Schaik E, van Vliet EI, Feelders RA, Krenning EP, Khan S, Kamp K, Valkema R, van Nederveen FH, Teunissen JJ, Kwekkeboom DJ, de Herder WW (2011) Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. J Clin Endocrinol Metab 96(11):3381–3389. https://doi.org/10.1210/jc.2011-1563 CrossRefPubMed van Schaik E, van Vliet EI, Feelders RA, Krenning EP, Khan S, Kamp K, Valkema R, van Nederveen FH, Teunissen JJ, Kwekkeboom DJ, de Herder WW (2011) Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. J Clin Endocrinol Metab 96(11):3381–3389. https://​doi.​org/​10.​1210/​jc.​2011-1563 CrossRefPubMed
9.
10.
Zurück zum Zitat Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Oberg K (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2):172–185. https://doi.org/10.1159/000443167 CrossRefPubMed Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Oberg K (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2):172–185. https://​doi.​org/​10.​1159/​000443167 CrossRefPubMed
14.
Zurück zum Zitat Usukura M, Yoneda T, Oda N, Yamamoto Y, Takata H, Hasatani K, Takeda Y (2007) Medical treatment of benign insulinoma using octreotide LAR: a case report. Endocr J 54(1):95–101CrossRefPubMed Usukura M, Yoneda T, Oda N, Yamamoto Y, Takata H, Hasatani K, Takeda Y (2007) Medical treatment of benign insulinoma using octreotide LAR: a case report. Endocr J 54(1):95–101CrossRefPubMed
15.
16.
Zurück zum Zitat Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA (1989) Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol 121(1):34–40CrossRefPubMed Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA (1989) Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol 121(1):34–40CrossRefPubMed
17.
Zurück zum Zitat Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, O’Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nuclear Med Mol Imaging 40(5):800–816. https://doi.org/10.1007/s00259-012-2330-6 CrossRef Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, O’Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nuclear Med Mol Imaging 40(5):800–816. https://​doi.​org/​10.​1007/​s00259-012-2330-6 CrossRef
19.
Zurück zum Zitat Goode PN, Farndon JR, Anderson J, Johnston ID, Morte JA (1986) Diazoxide in the management of patients with insulinoma. World J Surg 10(4):586–592CrossRefPubMed Goode PN, Farndon JR, Anderson J, Johnston ID, Morte JA (1986) Diazoxide in the management of patients with insulinoma. World J Surg 10(4):586–592CrossRefPubMed
20.
Zurück zum Zitat Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET (2007) Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas—predominance of receptor subtype 4. Endocr Pathol 18(2):79–85CrossRefPubMed Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET (2007) Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas—predominance of receptor subtype 4. Endocr Pathol 18(2):79–85CrossRefPubMed
22.
Zurück zum Zitat Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513. https://doi.org/10.1056/NEJMoa1003825 CrossRefPubMed Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513. https://​doi.​org/​10.​1056/​NEJMoa1003825 CrossRefPubMed
23.
Zurück zum Zitat Komori Y, Yada K, Ohta M, Uchida H, Iwashita Y, Fukuzawa K, Kashima K, Yokoyama S, Inomata M, Kitano S (2014) Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors. J Hepato Biliary Pancreat Sci 21(4):288–295. https://doi.org/10.1002/jhbp.26 CrossRef Komori Y, Yada K, Ohta M, Uchida H, Iwashita Y, Fukuzawa K, Kashima K, Yokoyama S, Inomata M, Kitano S (2014) Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors. J Hepato Biliary Pancreat Sci 21(4):288–295. https://​doi.​org/​10.​1002/​jhbp.​26 CrossRef
25.
Zurück zum Zitat Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N (2017) Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary. Neuroendocrinology. https://doi.org/10.1159/000477585 CrossRefPubMed Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N (2017) Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary. Neuroendocrinology. https://​doi.​org/​10.​1159/​000477585 CrossRefPubMed
28.
Zurück zum Zitat Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O’Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Oberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E (2017) Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376(2):125–135. https://doi.org/10.1056/NEJMoa1607427 CrossRefPubMedPubMedCentral Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O’Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Oberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E (2017) Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376(2):125–135. https://​doi.​org/​10.​1056/​NEJMoa1607427 CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Sampaio IL, Luiz HV, Violante LS, Santos AP, Antunes L, Torres I, Sanches C, Azevedo I, Duarte H (2016) Treatment of gastroenteropancreatic neuroendocrine tumors with 177Lu-DOTA-TATE: experience of the Portuguese Institute of Oncology in Porto. Acta Med Port 29(11):726–733. https://doi.org/10.20344/amp.7306 CrossRefPubMed Sampaio IL, Luiz HV, Violante LS, Santos AP, Antunes L, Torres I, Sanches C, Azevedo I, Duarte H (2016) Treatment of gastroenteropancreatic neuroendocrine tumors with 177Lu-DOTA-TATE: experience of the Portuguese Institute of Oncology in Porto. Acta Med Port 29(11):726–733. https://​doi.​org/​10.​20344/​amp.​7306 CrossRefPubMed
35.
Zurück zum Zitat Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, Lepensky C, Kwekkeboom DJ, Baum RP, Krenning EP, Modlin IM (2015) Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 42(1):5–19. https://doi.org/10.1007/s00259-014-2893-5 CrossRefPubMed Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, Lepensky C, Kwekkeboom DJ, Baum RP, Krenning EP, Modlin IM (2015) Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 42(1):5–19. https://​doi.​org/​10.​1007/​s00259-014-2893-5 CrossRefPubMed
Metadaten
Titel
Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review
verfasst von
D. Magalhães
I. L. Sampaio
G. Ferreira
P. Bogalho
D. Martins-Branco
R. Santos
H. Duarte
Publikationsdatum
01.03.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 3/2019
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-018-0911-3

Weitere Artikel der Ausgabe 3/2019

Journal of Endocrinological Investigation 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.